Neurology Central

Cromolyn sodium delays symptoms of ALS in mice, study reveals


A research group from Massachusetts General Hospital (MA, USA) have suggested that the US FDA-approved drug cromolyn sodium could be effective against amyotrophic lateral sclerosis (ALS). The results of their paper, published in Scientific Reports, demonstrated that disease progression was delayed in a mouse model of ALS following injection of the drug. 

Recent evidence suggests that ALS may develop as a result of inflammatory processes. To explore this connection, the authors of the paper investigated whether cromolyn sodium could impact disease development. Cromolyn sodium is an anti-inflammatory drug currently approved by the FDA for the treatment of asthma and other inflammatory conditions. 

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.